4D Molecular Therapeutics(FDMT) - 2024 Q1 - Quarterly Results

Exhibit 99.1 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights EMERYVILLE, Calif., May. 9, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today reported first quarter 2024 financial results and provided operational highlights. "The first quarter of 2024 kicks off another transformative year for 4DMT ...